170 related articles for article (PubMed ID: 18419049)
1. Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.
Chin LT; Chu C; Chen HM; Wang DW; Liao SK
Chang Gung Med J; 2008; 31(1):1-15. PubMed ID: 18419049
[TBL] [Abstract][Full Text] [Related]
2. Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells.
Hoff H; Knieke K; Cabail Z; Hirseland H; Vratsanos G; Burmester GR; Jorch G; Nadler SG; Bröker B; Hebel K; Brunner-Weinzierl MC
J Immunol; 2009 May; 182(9):5342-51. PubMed ID: 19380781
[TBL] [Abstract][Full Text] [Related]
3. Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.
Chin LT; Chu C; Chen HM; Hsu SC; Weng BC; Chu CH
BMC Biotechnol; 2007 Aug; 7():51. PubMed ID: 17714596
[TBL] [Abstract][Full Text] [Related]
4. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
5. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.
Wing K; Yamaguchi T; Sakaguchi S
Trends Immunol; 2011 Sep; 32(9):428-33. PubMed ID: 21723783
[TBL] [Abstract][Full Text] [Related]
6. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.
Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M
Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799
[TBL] [Abstract][Full Text] [Related]
7. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 control over Foxp3+ regulatory T cell function.
Wing K; Onishi Y; Prieto-Martin P; Yamaguchi T; Miyara M; Fehervari Z; Nomura T; Sakaguchi S
Science; 2008 Oct; 322(5899):271-5. PubMed ID: 18845758
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice.
Kolar P; Knieke K; Hegel JK; Quandt D; Burmester GR; Hoff H; Brunner-Weinzierl MC
Arthritis Rheum; 2009 Jan; 60(1):123-32. PubMed ID: 19116935
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 (CD152) and its involvement in autoimmune disease.
Holmberg D; Cilio CM; Lundholm M; Motta V
Autoimmunity; 2005 May; 38(3):225-33. PubMed ID: 16126511
[TBL] [Abstract][Full Text] [Related]
12. Altering immune tolerance therapeutically: the power of negative thinking.
Prud'homme GJ
J Leukoc Biol; 2004 Apr; 75(4):586-99. PubMed ID: 14657212
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4: negative regulator of the immune response and a target for cancer therapy.
Keilholz U
J Immunother; 2008 Jun; 31(5):431-9. PubMed ID: 18463542
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 blockade: autoimmunity as treatment.
Kapadia D; Fong L
J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
[No Abstract] [Full Text] [Related]
15. Anticytotoxic T lymphocyte-associated antigen 4 treatment--can melanoma be cured at the expense of autoimmune disorders?
Lejeune FJ
Melanoma Res; 2006 Oct; 16(5):377-8. PubMed ID: 17013085
[No Abstract] [Full Text] [Related]
16. Molecular modeling of CD28 and three-dimensional analysis of residue conservation in the CD28/CD152 family.
Bajorath J; Metzler WJ; Linsley PS
J Mol Graph Model; 1997 Apr; 15(2):135-9, 108-11. PubMed ID: 9385561
[TBL] [Abstract][Full Text] [Related]
17. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation.
Kakoulidou M; Giscombe R; Zhao X; Lefvert AK; Wang X
Scand J Immunol; 2007 Nov; 66(5):529-37. PubMed ID: 17953528
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies.
Weber JS
Melanoma Res; 2006 Oct; 16(5):379-83. PubMed ID: 17013086
[TBL] [Abstract][Full Text] [Related]
19. [The surface CD152 (CTLA-4) expression on peripheral blood lymphocytes in children with Hashimoto's thyroiditis].
Kucharska A; Górska E; Popko K; Wasik M; Rymkiewicz-Kluczyńska B
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):167-70. PubMed ID: 17020649
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
Murillo O; Arina A; Tirapu I; Alfaro C; Mazzolini G; Palencia B; López-Diaz De Cerio A; Prieto J; Bendandi M; Melero I
Clin Cancer Res; 2003 Nov; 9(15):5454-64. PubMed ID: 14654524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
